CRP production is stimulated by IL-6 [36], and inhibitors of IL-6 are currently being investigated in HFpEF with hsCRP ≥ 2 mg/L in the Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation (HERMES) trial [37]. Here, CRP is linked to heart failure.